We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Multi-Omics Approach Guides Relapsed Multiple Myeloma Treatment

By LabMedica International staff writers
Posted on 30 Aug 2018
Many patients with relapsed multiple myeloma are not often matched with correct treatment options in a timely or personalized manner, and most patients have a median survival rate of six years. More...
With standard diagnosis and treatment, relapses are usually inevitable and fatal for most patients.

The use of high-throughput DNA sequencing to match genetic mutations to cancer-killing drugs, allows treatment for patients with multiple myeloma. Sequencing has revealed wide heterogeneity across patients and complex sub-clonal structures, indicating that using personalized therapeutic approach can help improve patients with myeloma.

Scientists at the Mount Sinai Hospital (New York, NY, USA) and their colleagues performed a precision medicine trial using a group of 64 relapsed multiple myeloma patients. They collected 4 to 10 mL of bone aspirate, as well as peripheral blood samples, and extracted tumor genomic DNA and RNA from BM CD138+ cells. Whole-exome sequencing (WES) and RNA sequencing libraries were submitted to Illumina HiSeq2500 for paired-end sequencing (100 base pairs). Targeted sequencing was performed using the Lymphoma Extended targeted next-generation sequencing panel from Cancer Genetics.

The team generated treatment recommendations in 63 of 64 patients. Twenty-six patients had treatment implemented, and 21 were assessable. Of these, 11 received a drug that was based on RNA findings, eight received a drug that was based on DNA, and two received a drug that was based on both RNA and DNA. Sixteen of the 21 evaluable patients had a clinical response (i.e. reduction of disease marker ≥ 25%), giving a clinical benefit rate of 76% and an overall response rate of 66%, with five patients having ongoing responses at the end of the trial. The median duration of response was 131 days.

The authors concluded that a comprehensive sequencing approach can identify viable options in patients with relapsed and/or refractory myeloma, and they represent proof of principle of how RNA sequencing can contribute beyond DNA mutation analysis to the development of a reliable drug recommendation tool. The study was published in the August 2018 issue of the journal JCO Precision Oncology.

Related Links:
Mount Sinai Hospital



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Portable Electronic Pipette
Mini 96
New
Human Estradiol Assay
Human Estradiol CLIA Kit
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Pathology

view channel
Image: Erythrocyte Sedimentation Rate Sample Stability (Photo courtesy of ALCOR Scientific)

ESR Testing Breakthrough Extends Blood Sample Stability from 4 to 28 Hours

Erythrocyte sedimentation rate (ESR) is one of the most widely ordered blood tests worldwide, helping clinicians detect and monitor infections, autoimmune conditions, cancers, and other diseases.... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.